We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
Moderna has signed a memorandum of understanding (MoU) with the government of Canada to start domestic production of messenger RNA (mRNA) vaccines through a new manufacturing facility in
AstraZeneca has received the European Commission (EC) approval for Forxiga (dapagliflozin) to treat chronic kidney disease (CKD) in adults, regardless of type-2 diabetes (T2D). Forxiga is an oral,
Roche announced that the Phase 3 POLARIX trial of its cancer drug Polivy (polatuzumab vedotin) has met the primary endpoint. The Phase 3 trial evaluated the efficacy, safety
Sanofi has received the US Food and Drug Administration (FDA) approval for Nexviazyme (avalglucosidase alfa-ngpt) to treat a type of Pompe disease. Nexviazyme is an enzyme replacement therapy
Johnson & Johnson (J&J) has received the regulatory authorisation for its single-dose Covid-19 vaccine, developed by its subsidiary Janssen, for emergency use in India. Last Friday, the US
Bayer has acquired US-based biopharmaceutical company Vividion Therapeutics for an upfront consideration of $1.5bn and potential milestone payments of up to $500m. Vividion is engaged in developing precision
Novavax along with its partner Serum Institute of India (SII) has filed regulatory submissions with the Drugs Controller General of India (DCGI) and regulatory agencies in Indonesia and
Japanese conglomerate SoftBank Group has purchased a non-voting stake worth $5bn in Swiss pharmaceutical company Roche. With the newly acquired stake, SoftBank becomes one of Roche’s biggest stakeholders,
Pfizer has unveiled positive top-line results from the Phase 2b/3 ALLEGRO trial evaluating ritlecitinib, its once-daily oral treatment for alopecia areata. Alopecia areata is an autoimmune disease characterized
Sanofi has agreed to acquire clinical-stage mRNA therapeutics company Translate Bio to advance the application of mRNA technology in the development of therapeutics and vaccines. Under the agreement,